QIAGEN N.V. (QGEN)
Qiagen (QGEN) Reports Q4 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Qiagen (QGEN) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Qiagen (QGEN) Q4 Earnings Lag Estimates
Qiagen (QGEN) came out with quarterly earnings of $0.61 per share, missing the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.57 per share a year ago.
Is QIAGEN Stock an Apt Pick for Your Portfolio Right Now?
QGEN stays on investors' radar due to its robust expansion of testing menu and benefits from strategic ties.
Qiagen (QGEN) Reports Next Week: Wall Street Expects Earnings Growth
Qiagen (QGEN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Strategic Collaborations Aid QGEN Stock Amid Competition
QIAGEN invests heavily in research and development to support internal growth, including the menu expansion of its key platforms.
Will Qiagen (QGEN) Beat Estimates Again in Its Next Earnings Report?
Qiagen (QGEN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
QGEN Stock Might Rise Following Partnership With Genomics England
QIAGEN partners with Genomics England to support the United Kingdom's initiative to sequence the genomes of 100,000 newborns with expert-curated genomic content.
New Product Offerings Support QIAGEN's Shares Amid Currency Woes
To support internal growth, QIAGEN is investing heavily in R&D for menu expansion of its key platforms.
Here's Why Qiagen (QGEN) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Why Qiagen (QGEN) is a Top Momentum Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
QIAGEN Stock Might Rise Following 1000 EZ2 Connect Placements
QGEN achieves milestone with more than 1,000 EZ2 Connect placements worldwide, contributing to a global installed base of over 5,500 EZ series instruments.
Should You Continue to Retain QIAGEN Stock in Your Portfolio Now?
QGEN's robust expansion of its testing menu and potential in molecular diagnostics bode well for investors.
